This Funding Opportunity Announcement (FOA) invites applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through controlled manipulation of beta cell replication or islet cell plasticity, reprogramming of non-beta cells into beta-like cells, or shielding of residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN).
Deadlines:
- Letter of Intent Due Date(s): September 26, 2022
- Application Due Date(s): October 26, 2022
RFA-DK-22-009 Expiration Date October 27, 2022
Amount Description
Application budgets are limited to $600,000 direct costs per year.
The maximum project period is 4 years.